公开(公告)号：US11214627B2

公开(公告)日：2022-01-04

申请号：US16307454

申请日：2017-06-08

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph Adams ,  Thomas Allen Ceska ,  Anna Marie Davies ,  Alistair James Henry ,  Xiaofeng Liu ,  James Michael McDonnell ,  Brian John Sutton ,  Marta Katarzyna Westwood

IPC: C07K16/42 ,  C07K16/28 ,  C07K14/735 ,  A61P37/08

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

公开(公告)号：US20240352083A1

公开(公告)日：2024-10-24

申请号：US18647911

申请日：2024-04-26

Applicant: UCB Biopharma SRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Xiaofeng Liu

IPC: C07K14/54 ,  C07K14/505 ,  C07K14/535 ,  C07K14/55 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K14/5443 ,  C07K14/505 ,  C07K14/535 ,  C07K14/5428 ,  C07K14/55 ,  C07K16/18 ,  C07K16/244 ,  C07K16/248 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

公开(公告)号：US12054559B2

公开(公告)日：2024-08-06

申请号：US17541932

申请日：2021-12-03

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph Adams ,  Thomas Allen Ceska ,  Anna Marie Davies ,  Alistair James Henry ,  Xiaofeng Liu ,  James Michael McDonnell ,  Brian John Sutton ,  Marta Katarzyna Westwood

IPC: C07K16/42 ,  A61P37/08 ,  C07K14/735 ,  C07K16/28

CPC classification number: C07K16/4291 ,  A61P37/08 ,  C07K14/70535 ,  C07K16/2851 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

公开(公告)号：US11999772B2

公开(公告)日：2024-06-04

申请号：US17259090

申请日：2019-07-10

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Xiaofeng Liu

IPC: C07K16/00 ,  C07K14/505 ,  C07K14/535 ,  C07K14/54 ,  C07K14/55 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K14/5443 ,  C07K14/505 ,  C07K14/535 ,  C07K14/5428 ,  C07K14/55 ,  C07K16/18 ,  C07K16/244 ,  C07K16/248 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

公开(公告)号：US11942188B2

公开(公告)日：2024-03-26

申请号：US16823055

申请日：2020-03-18

Applicant: UCB Biopharma SRL

Inventor： Jiye Shi ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Xiaofeng Liu

IPC: G16C20/50 ,  C07K16/24 ,  G16B5/00 ,  G16B15/00 ,  G16B15/30 ,  G16C20/90

CPC classification number: G16B5/00 ,  C07K16/244 ,  G16B15/30 ,  G16C20/50 ,  G16C20/90 ,  C07K2317/55 ,  C07K2317/76 ,  G16B15/00

Abstract: Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.

公开(公告)号：US20220073581A1

公开(公告)日：2022-03-10

申请号：US17259090

申请日：2019-07-10

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Xiaofeng Liu

IPC: C07K14/54 ,  C07K16/24 ,  C07K16/18 ,  C07K16/28 ,  C07K14/55 ,  C07K14/535 ,  C07K14/505

Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

公开(公告)号：US20210005277A1

公开(公告)日：2021-01-07

申请号：US16823055

申请日：2020-03-18

Applicant: UCB Biopharma SRL

Inventor： Jiye Shi ,  Terence Seward Baker ,  Alastair David Griffiths Lawson ,  Xiaofeng Liu

IPC: G16B5/00 ,  G16C20/90 ,  G16C20/50 ,  C07K16/24

Abstract: Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.